Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy by Morís G et al.
 
 
 
 
 
 
 
Morís G, Wood L, Fernández-Torrón R, Coraspe JAG, Turner C, Hilton-Jones D, 
Norwood F, Willis T, Parton M, Rogers M, Hammans S, Roberts M, Househam 
E, Williams M, Lochmüller H, Evangelista T. Chronic pain has a strong impact on 
quality of life in facioscapulohumeral muscular dystrophy. Muscle and 
Nerve 2017, DOI: 10.1002/mus.25991.
DOI link 
https://doi.org/10.1002/mus.25991 
ePrints link 
http://eprint.ncl.ac.uk/pub_details2.aspx?pub_id=243351 
Date deposited 
29/11/2017 
Copyright 
© 2017 The Authors Muscle & Nerve Published by Wiley Periodicals, Inc. 
This is an open access article under the terms of the Creative Commons Attribution 
License, which permits use, distribution and reproduction in any medium, provided the 
original work is properly cited. 
Licence 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
CHRONIC PAIN HAS A STRONG IMPACT ON QUALITY OF LIFE IN
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
GERMAN MORIS, MD ,1 LIBBY WOOD, BSc (HONS),1 ROBERTO FERNANDEZ-TORRON, MD,1,2,3,4
JOSE ANDRES GONZALEZ CORASPE, MD,1 CHRIS TURNER, MD,5 DAVID HILTON-JONES, MD,6 FIONA NORWOOD, MD,7
TRACEY WILLIS, MD,8 MATT PARTON, MD,5 MARK ROGERS, MD,9 SIMON HAMMANS, MD,10 MARK ROBERTS, MD,11
ELIZABETH HOUSEHAM, MD,12 MAGGIE WILLIAMS, BSc (HONS),13 HANNS LOCHM€ULLER, MD,1 and
TERESINHA EVANGELISTA, MD1
1 MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Central Parkway Newcastle upon Tyne
NE1 3 BZ, United Kingdom
2 Neuromuscular Disorders Unit, Neurology Department, Hospital Donostia, San Sebastian, Spain
3 Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Spain
4 Center for Biomedical Research in the Neurodegenerative Diseases (CIBERNED) Network, Instituto Carlos III, Ministry of Economy
and Competitiviness, Madrid, Spain
5 UCL MRC Centre for Neuromuscular Diseases, Institute of Neurology, London, United Kingdom
6 Department of Clinical Neurology, John Radcliffe Hospital, Oxford, United Kingdom
7 Department of Neurology, King’s College Hospital, London, United Kingdom
8 The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom
9 Institute of Medical Genetics, University Hospital of Wales, Cardiff, United Kingdom
10 Wessex Neurological Centre, University Hospital of Southampton, Southampton, United Kingdom
11 Department of Neurology, Salford Royal NHS Foundation Trust, Salford, United Kingdom
12 Department of Neurology, Derriford Hospital, Plymouth Hospitals NHS Trust, Plymouth, United Kingdom
13 Bristol Genetics Laboratory, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
Accepted 14 October 2017
ABSTRACT: Introduction: Earlier small case series and clini-
cal observations reported on chronic pain playing an important
role in facioscapulohumeral dystrophy (FSHD). The aim of this
study was to determine the characteristics and impact of pain
on quality of life (QoL) in patients with FSHD. Methods: We
analyzed patient reported outcome measures collected through
the U.K. FSHD Patient Registry. Results: Of 398 patients,
88.6% reported pain at the time of study. The most frequent
locations were shoulders and lower back. A total of 203 partici-
pants reported chronic pain, 30.4% of them as severe. The
overall disease impact on QoL was significantly higher in
patients with early onset and long disease duration. Chronic
pain had a negative impact on all Individualised Neuromuscular
Quality of Life Questionnaire domains and overall disease
score. Conclusions: Our study shows that pain in FSHD type 1
(FSHD1) is frequent and strongly impacts on QoL, similar to
other chronic, painful disorders. Management of pain should be
considered when treating FSHD1 patients.
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Facioscapulohumeral muscular dystrophy (FSHD)
is the second most common muscle condition in
adults, with an overall incidence of 1:20,000.1,2
FSHD is an autosomal dominant and genetically
heterogeneous disorder; in 95% of patients
(FSHD1), it is associated with the loss of part of a
D4Z4 repeated sequence in chromosome 4q35. In
5% of patients (FSHD2), mutations in the struc-
tural maintenance of chromosomes flexible hinge
domain containing 1 (SMCHD1) gene are found.
The D4Z4 methylation status changes in FSHD
and the D4Z4 hypomethylation leads to chromatin
relaxation of D4Z4 and expression of DUX4.3
FSHD symptoms usually start around the sec-
ond decade and are most commonly characterized
by asymmetric weakness affecting the face, shoul-
der, and arms, followed by the distal lower extremi-
ties and pelvic girdle. Not all patients have the
complete phenotype of FSHD, and clinical severity
varies widely among patients, including great vari-
ability of weakness within families. Chronic pain is
a significant problem in different neuromuscular
conditions,4,5 such as limb-girdle muscular dystro-
phy 1C, myotonic dystrophies, and FSHD6,7; in
some cases, pain may even be the first disease man-
ifestation.8,9 Reports about pain in FSHD-
phenotype patients predate the development of
genetic testing.
Additional supporting information may be found in the online version of
this article.
Abbreviations: FSHD, facioscapulohumeral muscular dystrophy; FSHD1,
facioscapulohumeral muscular dystrophy type 1; INQoL, Individualised
Neuromuscular Quality of Life Questionnaire; IR, interquartile range;
JWMDRC, John Walton Muscular Dystrophy Research Centre; NSAIDs,
nonsteroidal anti-inflammatory drugs; QoL, quality of life; PROM, patient
reported outcome measures; SF-MPQ, Short Form of the McGill Pain
Questionnaire; SMCHD1, structural maintenance of chromosomes flexible
hinge domain containing 1.
Key words: facioscapulohumeral dystrophy; INQoL; pain; patient regis-
try; patient reported outcome measures; quality of life
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Recent studies have suggested that pain may be
present in the majority of FSHD patients, ranging
from 76% to more than 80% of the FSHD popula-
tion, with 19% reporting severe pain.5,10–16 In some
cases, FSHD patients reported severe, difficult to
control, multifocal muscle pain as the most dis-
abling aspect of their condition.9 Even so, pain is
often undertreated. Some studies have shown that
pain in FSHD negatively impacts quality of life
(QoL) and increases disease burden.13,15 However,
the data available is scarce, often not FSHD-specific
and usually clinician-reported. The studies address
small heterogeneous cohorts that include other
neuromuscular disorders.5,10 Moreover, epidemiol-
ogy, etiology, pathophysiology, and management of
pain have not yet been addressed, nor has the inter-
action between pain and its impact on QoL.
The aim of the study was to determine the fre-
quency, localization, and intensity of pain in the
FSHD1 population registered in the U.K. FSHD reg-
istry; and to evaluate the influence of pain, age, sex,
disease duration, and ambulatory status on QoL.
MATERIALS AND METHODS
Patients and Setting. We have analyzed data obtained
from the U.K. FSHD Patient Registry that is curated from
the John Walton Muscular Dystrophy Research Centre
(JWMDRC) at Newcastle University (https://www.fshd-regis-
try.org/uk/participants/questionnaires/index.en.html).
The Registry started in May 2013. A cutoff point for data
analysis was established in February 2017. This patient
driven registry17 is based on the recommendations reported
at the 171st European Neuromuscular Centre workshop on
the care and management of FSHD.18 In addition to these
items, several patient reported outcome measures (PROM)
on pain and QoL and were added after consultation with
the patient community about their own research priorities.
The registry has received full ethical (Newcastle and North
Tyneside 113/NE/0048, February 2013), management
(Newcastle upon Tyne Hospitals Trust R&D 6573, February
2013), and data protection (Caldicott February 2013)
approvals.
Measures. Pain. The Short Form of the McGill Pain
Questionnaire (SF-MPQ) was used to report pain. The SF-
MPQ is widely used, well-validated, and reliable and has previ-
ously been used in FSHD1.19 The SF-MPQ consists of 15
descriptors (11 sensory and 4 affective) which are rated on an
intensity scale as 05none, 15mild, 25moderate or
35 severe, with higher scores representing more pain. Sensory
(ranging from 0 to 33), affective (ranging from 0 to 12), and
total pain scores (ranging from 0 to 45) and Present Pain
Intensity Index (ranging from 0 to 5) were analyzed. An
FSHD specific PROM, named universal pain assessment tool,
developed by the multi-disciplinary team at JWMDRC was also
used. The universal pain assessment tool is in the process of
validation and it includes sections on pain intensity, current
pain and chronic pain, and in addition questions regarding
medication and other nonpharmacological therapies (sections
of the universal pain assessment tool used in this study are
shown in Supplementary Table S1, which is available online).
For the purpose of the study, “current pain” was defined as
any pain experienced in the last 7 days and “chronic pain” as
any persistent pain experienced for at least 12 weeks within a
year in the last 5 years. The universal pain assessment tool
clearly provided the time definition of current and chronic
pain according to study pain definitions. To analyze pain
intensity, the pain was considered to be severe when reported
as horrible or excruciating.
Individualized Neuromuscular Quality of Life Ques-
tionnaire. Patients completed the Individualised Neuro-
muscular Quality of Life Questionnaire (INQoL), a widely
used and well-validated neuromuscular disease specific mea-
sure of QoL.20,21 The final score for each section and total
INQoL score is presented as a percentage of the maximum
detrimental impact where 100 is the greatest impact on QoL.
Data Analysis. Location and dispersion indexes of non-
continuous variables were used to describe the sample with
median and interquartile range (IR). Categorical variables
were described as percentages. All statistics discussed here
are presented as percentages of the total patient answers
and not as percentages of the whole cohort unless otherwise
stated. For comparison between groups, Chi-square tests,
Mann-Whitney U test, and Kruskal-Wallis test were used, as
appropriate. Correlations were calculated using nonpara-
metric Spearman’s coefficient. To evaluate influence of age,
age of onset, disease duration, gender, D4Z4 repeat, SF-
MPQ total score, and chronic pain on INQoL we performed
a multivariate linear regression. Differences were considered
significant at P< 0.05, and all statistical tests were two tailed.
All data were analyzed with IBM SPSS Statistics 22.
RESULTS
Clinical Data. Four hundred and two genetically
confirmed FSHD1 patients were included in this
study. Figure 1 shows the progress of participants
FIGURE 1. Flow diagram of the progress of participants
included in the U.K. FSHD Patient Registry and the number of
patients excluded.
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included. In total, 398 patients have been included
for further analysis. All patients are followed-up by
neurologists with experience in neuromuscular dis-
orders to ensure the FSHD1 diagnosis. Of these 398
UK genetically confirmed FSHD1 patients, 383
(96.2%) answered the SF-MPQ, 367 (92.2%) and
365 (91.7%) answered current and chronic pain
questions in the universal pain assessment tool,
respectively, and 340 (85.4%) provided answers to
INQoL.
The median age of the entire cohort was 47.0
(interquartile range: 60.6) years. Demographic
data is presented in Table 1. In 6 patients, the size
of the p13E-11 EcoRI fragments was> 39 kb (3
patients had 39 kb, and 3 patients had 40, 41, and
45 kb, respectively); although, they have neither
SMCHD1 test nor methylation studies. These 6
patients were included in the study because all
reported symptoms and the treating neuromuscu-
lar specialist confirmed clinical features consistent
with FSHD. There was no EcoRI fragment informa-
tion in 45 of the cases.
Pain. Of those completing the SF-MPQ, 339
patients (88.5%) reported experiencing pain to
some degree. The sensory score in females was sig-
nificantly higher (P< 0.05) than in males (Table 1).
Three hundred and twenty-five (88.6%) participants
reported experiencing current pain. Figure 2 shows
the percentage of patients that reported the highest
levels of pain and the pain severity in different loca-
tions. The severe lower back pain was reported
more frequently in females (33 patients; 17.7%)
than in males (14 patients; 11.2%) with statistical
significance (P< 0.05). No significant differences
were observed regarding current pain localization
across EcoRI fragments size, age of onset or motor
function as showed in Table 2. Of the 365 respond-
ers, 203 (55.6%) people reported experiencing
chronic pain, 69 patients (30.4%) reported this
pain as severe. The chronic pain was more fre-
quently reported in females (111 patients; 61.0%)
than in males (92 patients, 50.3%) (P< 0.05). The
most common location of chronic pain was the
shoulder joint in 165 patients (45%). No association
was seen between chronic pain and EcoRI fragments
size, age of onset, or motor function.
Therapies. Medication to manage pain was taken
by 367 (92.2%) patients. When specified, nonste-
roidal anti-inflammatory drugs (NSAIDs) were the
most frequent drugs used followed by opioids as
described in Figure 3. Less than half of patients
(162 patients, 46.2%) have used physiotherapy to
help with pain management; a dramatic reduction
in pain was reported by 4.4% (7 patients). Sixty-
two patients (38.8%) reported some reduction in
pain, and 80 (50.0%) reported no reduction.
Eleven patients (6.9%) experienced an increase in
their pain after physiotherapy. We did not find any
Table 1. Demographic data and frequency of pain
Total Males Females
Epidemiological
Gender 398 197 (49.6%) 201 (50.4 %)
Age (years)* 47.0 (60.6) 48.0 (25.0) 46.0 (25.0)
Age onset (years)* 17.0 (21.2) 19.0 (22.0)† 13.5 (22.5)†
Disease duration (years)* 26.0 (27.0) 24.0 (22.5) 27.5 (30.7)
Genetic test (D4Z4 repeat kb)* 25.0 (10.0) 25.0 (10.0) 24.0 (11.3)
Motor function, total (%)
Ambulatory-unassisted 193 (49.4%) 91 (47.4%) 102 (51.3%)
Ambulatory-assisted 145 (37.1%) 78 (40.6%) 67 (33.7%)
Non-ambulatory 53 (13.6%) 23 (12.0%) 30 (15.1%)
Wheelchair use, total (%)
No use 244 (62.2%) 125 (65.1%) 119 (59.5%)
Part-time 94 (24.0%) 44 (22.9%) 50 (25.0%)
Full-time 54 (13.8%) 23 (12.0%) 31 (15.5%)
SF-MPQ
Presence of pain Total (%) 339 (85.2 %) 164 (83.2%) 175 (87.1%)
Sensory Score* 5.0 (9.0) 3.0 (9.0)‡ 6.0 (9.0)‡
Affective Score* 1.0 (3.0) 1.0 (3.0) 2.0 (4.0)
Total score* 6.0 (12.5) 5.0 (11.5) 7.0 (12.5)
Present Pain Intensity Index* 1.0 (2.0) 1.0* (2.0) 1.0 (1.0)
Chronic pain
Chronic pain Total (%) 203 (55.6%) 92 (50.3%)‡ 111 (61.0%)‡
Severe chronic pain Total (%) 69 (30.4%) 29 (26.6%) 40 (33.9%)
*Expressed in median and interquartile range.
†P< 0.01.
‡P< 0.05.
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FIGURE 2. Description of the localization and the severity of the current pain in each localization expressed in percentage. aPercent-
age of patients suffering current pain in each localization. bPercentage of patients suffering severe current pain (pain rated as horrible
or excruciating) in each localization.
Table 2. Characteristics of pain in different sub-groups of FSHD1 patients
Total
SF-MPQ*
Severe current pain
localizations Total (%) Chronic pain Total (%)
Total pain score Shoulder Lower back
Presence
chronic pain
Severe
chronic pain
Age of onset (years)
0-9 107 7.0 (9.0) 13 (17.8%) 19 (24.1 %) 62 (64.6 %) 23 (34.8%)
10-19 104 7.5 (13.0) 14 (20.9%) 11 (16.7%) 53 (54.6%) 19 (33.3%)
20-39 99 6.0 (13.0) 16 (23.5%) 11 (16.7%) 55 (58.5%) 22 (34.4%)
>40 56 5.0 (7.7) 7 (17.1%) 5 (13.5%) 27 (50.0%) 4 (13.3%)
Disease duration (years)
0-19 138 6.0 (12.0) 22 (22.7%) 13 (15.1%) 75 (56.4%) 22 (26.5%)
20-39 130 9.0 (13.0) 19 (20.2%) 22 (22.9%) 70 (57.4%) 30 (38.5%)
>40 98 12.0 (12.0) 9 (15.5%) 11 (16.7%) 52 (60.5%) 16 (28.6%)
Fragment size, total
18Kb 82 5.0 (14.0) 6 (13.6 %) 14 (25.9 %) 38 (54.3 %) 14 (33.3%)
>18Kb 271 6.0 (8.0) 39 (20.5%) 28 (15.5%) 144 (56.9%) 46 (28.9%)
Motor function
Ambulatory-unassisted 193 6.0 (10.0)† 17 (15.5%) 24 (18.9%) 95 (51.1%) 29 (27.4% )
Ambulatory-assisted 145 9.0 (13.0)† 27 (24.1%) 24 (22.9%) 83 (60.6%) 34 (37.4%)
Non-ambulatory 53 6.0 (11.0)† 3 (8.1%) 3 (9.7%) 28 (58.3%) 6 (20.0%)
*Expressed in median and interquartile range.
†P< 0.05.
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statistical difference in response to physiotherapy
between any groups studied. In this survey, 370
patients (93%) reported using nonpharmacologic
therapies to help manage pain (Fig. 4).
Quality of Life. The median overall INQoL score
was 53.1 (IR: 34.3) suggesting relatively moderate
sickness-related dysfunction in this group of
FSHD1 patients. The sub-domains with the highest
median scores, indicating the greatest impact on
QoL were muscle weakness, body image, and activi-
ties. The least impact on QoL is in the areas of
muscle locking and relationships. The weakness
score in males was significantly higher than in
females (P< 0.01). No other domain was affected
by gender (Table 3). A higher total INQol score is
seen in patients with a shorter EcoRI fragment
(P< 0.05). The overall INQol increases with statisti-
cal significance with younger age of onset (rho5 -
0.22) and longer disease duration (rho510.23)
(P< 0.05).
The pain INQoL score is higher in ambulant
populations (P< 0.01).SF-MPQ sensory, affective,
and total pain scores correlated with INQoL pain
score (rho510.79, rho51 0.68, rho51 0.80,
respectively, P< 0.01), and INQoL total score
(rho510.48, rho51 0.50, rho51 0.51, respec-
tively, P< 0.01). On the other hand, the presence
of severe pain in the shoulders, severe lower back
pain, chronic pain, and severe chronic pain corre-
lated with the INQoL pain score (rho510.54,
rho51 0.46, rho51 0.67, rho510.44, respec-
tively, P< 0.01), and the INQoL total score (rho5
10.32, rho51 0.29, rho51 0.38, rho510.29,
respectively, P< 0.01). Multiple regression analysis
showed that longer disease duration was related to
greater deterioration on INQol; interestingly, the
total SF-MPQ score and presence of chronic pain
was also directly related to an increase in total
INQoL scores as showed in Table 4.
DISCUSSION
This study demonstrates that pain is highly
prevalent in FSHD1. Our data are consistent with
previous studies carried out in smaller mixed dis-
ease cohorts, and supports the conclusion that
pain is a common complaint in patients with
FSHD1, similar to or possibly worse than in other
neuromuscular conditions, even though a direct
comparative study was not conducted.5,14 Further-
more, pain is reported in a higher percentage in
our cohort that would be expected in the general
population, where is ranges from 10% to 55%.22,23
The frequency and intensity of pain reported in
FIGURE 3. Most frequently pharmacological groups used to
manage pain.
FIGURE 4. Most frequently nonpharmacologic interventions
used to manage pain.
Table 3. INQoL subscale scores and overall score comparisons between genders, and absence or presence of chronic pain
INQoL
Gender Chronic pain
Total Males Females No Yes
Weakness score 63.2 (26.4) 73.7 (36.8)* 68.4 (47.4)* 57.9 (47.4)* 79.0 (31.6)*
Locking score 10.5 (22.4) 10.5 (10.5) 10.5 (13.2) 10.5 (0.0)* 10.5 (26.3)*
Pain score 44.7 (31.6) 31.6 (52.6) 36.8 (47.4) 10.5 (15.8)* 63.2 (42.2)*
Fatigue score 50.0 (34.2) 47.4 (52.6) 47.4 (52.6) 26.3 (42.1)* 68.4 (43.4)*
Activities score 57.4 (58.6) 52.8 (43.1) 53.2 (54.9) 37.0 (38.5)* 67.6 (37.3)*
Independence score 50.0 (64.6) 34.7 (53.5) 33.3 (55.6) 25.0 (35.4)* 55.6 (50.2)*
Relationship score 20.4 (16.7) 20.4 (28.7) 18.5 (35.6) 13.0 (21.3)* 30.6 (37.1)*
Feelings score 54.2 (56.2) 38.9 (42.4) 41.7 (39.6) 27.8 (33.3)* 50.0 (40.3)*
Body image score 59.7 (51.4) 55.6 (52.8) 58.3 (55.6) 41.7 (50.0)* 61.1 (50.0)*
QoL Score 53.1 (34.3) 52.2 (30.0) 51.1 (36.3) 41.1 (30.4)* 60.6 (29.5)*
Values are expressed in median and interquartile range.
*P< 0.01.
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our population are similar to what has been
reported previously in osteoarthritis or rheumatoid
arthritis.24,25 Chronic pain is a substantial problem
in FSHD1 and needs to be tackled in a holistic way
with exercise/physiotherapy, psychosocial interven-
tion and tailored pharmacological treatment.
Gender influences FSHD1 clinical expression.
Males are characterized by a lower age at onset of
motor impairment and by a more severe disabil-
ity.26 However, our data shows that female FSHD1
patients experience pain more frequently than
males, suggesting that clinical impairment is not
the only underlying factor leading to pain in
FSHD1 patients. Although commonly reported,
the mechanisms behind gender differences in pain
perception are unknown; biopsychosocial mecha-
nisms, influence of sex hormones or endogenous
opioid function have all been proposed.27–29 Fur-
ther research is required to explore if there is any
specific mechanism in FSHD1 contributing to gen-
der difference in pain.30
Pain was reported most frequently in the
shoulders and lower back. These localizations are
consistent with the findings of previous studies.10
We hypothesize that the degree of pain in these
two locations may be exacerbated by the fact that
the muscles in this region are amongst the weakest
muscle groups in FSHD1. The abnormal posture,
with forward shoulders and exaggerated lumbar
lordosis as a consequence of the weakness, may be
a cause of pain. Lumbosacral spine movements
and kinetics are essential to normal movement;
therefore, lower back pain might negatively impact
on the patients’ ability to stand or walk. This type
of pain could be partially due to the asymmetrical,
multifocal pattern of muscle involvement that in
itself affects movement, generating a circle of pain,
muscle atrophy, and functional impairment. Mus-
cular involvement of the hands is less common in
FSHD131; therefore, it is unsurprising that this was
an area where pain was less frequently reported.
These findings and the possible correlation of pain
with the areas of greater weakness suggest an inter-
esting area for future study. The development of
specific strategies to improve strength, flexibility,
and endurance in the areas most affected by pain,
could lead to an improvement in the patient’s
mobility as well as QoL.
FSHD1 is an inheritable muscular condition
with a progressive clinical course; therefore, we
would expect to see an association between
chronic pain and disease duration. No correlation
was seen between chronic pain and current age,
age of onset or disease duration. We may speculate
that the causes of pain in different age groups and
in patients with different disease duration times
may be attributed to different causes with inflam-
matory mechanisms and muscle pain probably
being more important in the early stages of disease
and mechanical problems associated with asymmet-
rical muscle atrophy and weakness being the cause
for pain later in the natural history of the disease.
These aspects need to be considered in future
studies to achieve an optimal management of pain.
Chronic pain and the severity of it were not sig-
nificantly correlated with the D4Z4 fragment size
or motor function; therefore, our data did not
confirm the relationship between genetic pattern,
patient ambulatory state, and chronic pain. Con-
versely, when considering “current pain” both with
the SF-MPQ and the universal pain assessment
tool, patients who had no mobility limitations had
a tendency to report less pain, as previously
reported10; but in terms of chronic pain, the fre-
quency of pain is similar in ambulatory and non-
ambulatory patients. This controversial data
warrant further studies to carefully assess the pres-
ence of different type of pain in FSHD1 patients.
More than 90% of the patients reported taking
medication, the most common treatments were
NSAIDs and opioids, used more frequently than in
previous studies. Physiotherapy was used to control
pain in half of the patients together with other
interventions. Although physiotherapy was reported
as beneficial by some patients, a small percentage
reported an exacerbation of the symptoms after the
treatment; whether this worsening is due to lack of
access to specialist physiotherapy for neuromuscular
diseases should be assessed. It is necessary to identify
whether there is a subgroup of FSHD1 patients who
may get worse with physiotherapy to improve the
therapeutic approach to these patients. On the
other hand, worsening of the pain due to disease
progression may be incorrectly attributed to therapy
by some patients. Our data confirm that there is no
consistent management of pain in FSHD1 and that
current methods are not adequately relieving pain.
Table 4. Association of INQol index with demographic, genetic,
and pain presence
INQoL index
Univariate
analysis (P)
Multivariate
analysis (beta, P)
Age 0.338 NI
Age of onset 0.001 -0.057, 0.323
Disease duration 0.001 10.173, 0.003
Gender 0.529 NI
D4Z4 repeat 0.062 NI
SF-MPQ total score 0.001 10.400, 0.001
Chronic pain 0.001 10.128, 0.029
Adjusted R2: 0.284
NI, not included in the multivariate analysis since it was non-significant in
univariate analysis.
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Evaluating the patient’s response to individual treat-
ment is warranted to develop optimal pain therapy
regimens in FSHD1 patients.
We have estimated QoL in this cohort using
INQoL. There are difficulties for assessing QoL in
neuromuscular diseases; therefore, there are few
comprehensive studies available. In general, it is
reported that QoL in patients with neuromuscular
diseases is low.7,14,32,33 INQoL has been highly rated
in terms of its conceptual and measurement model,
reliability, validity, and administrative burden in neu-
romuscular diseases.20 INQoL provides an overall
score along with results in different domains. It
should be noted that INQoL was not designed spe-
cifically for FSHD patients and, therefore, is limited
as a true measure of QoL for FSHD. Specifically,
INQoL includes questions regarding muscle locking,
which has no relevance to this population. In our
population, the INQoL domains having the biggest
impact were muscle weakness, activities, and body
image. The domain least affected, apart from muscle
locking, was relationships. Our study has shown that
patients perceive a deterioration in QoL with the
progression of the disease; the younger the age of
onset and the longer the disease duration, the
higher the patients’ perception of disability. More-
over, the perception of lower QoL was also related
to lower EcoRI fragment sizes. These results suggest
a relationship between genetic pattern, clinical sever-
ity, and perception of QoL.
The analysis of our data shows that chronic pain
has a major negative impact on the QoL in FSHD1
consistent with the literature.13,15 Future research
should focus on the identification of the features of
pain with the greatest impact on QoL. This may sup-
port the development of effective treatments.
In this study, all the questionnaires were
patient reported17 without input from clinicians.
This gives information about how patients perceive
pain and QoL. PROM are an extraordinarily useful
tool, favored by regulatory agencies, for monitor-
ing the impact of care on patient well-being and
Qol.34
There are limitations to patient-reported data
and the element of self-selection to the registry
should not be ignored. An important limitation of
the current study is the lack of information on phys-
ical examination/strength measures; more severely
clinically affected individuals may be more likely to
experience shoulder and back pain. The patient
population may represent the most engaged and
active patients who may not be representative of the
entire FSHD1 population; however, our data are in
line with previously published studies. Furthermore,
our study could be improved through the inclusion
of longitudinal data, assessing changes in pain and
QoL over time. Finally, one of the pain
questionnaires (universal pain assessment tool) has
not yet been validated; however, there was a good
correlation with the well-validated SF-MPQ. In
answering the universal pain assessment tool, it is
important to clarify that patients have to recognize
the pain as a result of their FSHD, and that it may
be difficult to differentiate this pain from other
types of pain.
In conclusion, pain is a frequent symptom in
FSHD1 that negatively impacts QoL. Studies have
demonstrated that pain in FSHD1 is an inherent
feature of the condition that requires further inves-
tigations to understand the pathophysiology, to
study the relation with disease severity and func-
tional disability.
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